223 related articles for article (PubMed ID: 15852251)
1. Diverse effects of infliximab and etanercept on T lymphocytes.
Sieper J; Van Den Brande J
Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
[TBL] [Abstract][Full Text] [Related]
2. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
van den Brande J; Hommes DW; Peppelenbosch MP
J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
[TBL] [Abstract][Full Text] [Related]
3. [Anti-TNF alfa therapy in ankylosing spondylitis].
Cravo AR; Tavares V; Da Silva JC
Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
[TBL] [Abstract][Full Text] [Related]
4. [Anti-TNF-alpha treatment and spondyloarthropathies].
Braun Y; Balbir-Gurman A
Harefuah; 2002 Nov; 141(11):965-8, 1010. PubMed ID: 12476631
[TBL] [Abstract][Full Text] [Related]
5. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
[TBL] [Abstract][Full Text] [Related]
6. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.
Haraoui B; Krelenbaum M
Semin Arthritis Rheum; 2009 Dec; 39(3):176-81. PubMed ID: 18706681
[TBL] [Abstract][Full Text] [Related]
7. The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.
Xu M; Lin Z; Deng X; Li L; Wei Y; Liao Z; Li Q; Wei Q; Hu Z; Zhang Y; Lin Q; Huang J; Li T; Pan Y; Wu Y; Jin O; Yu B; Gu J
Rheumatology (Oxford); 2011 Aug; 50(8):1466-72. PubMed ID: 21441550
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-alpha therapy in ankylosing spondylitis.
De Keyser F; Van den Bosch F; Mielants H
Cytokine; 2006 Mar; 33(5):294-8. PubMed ID: 16516484
[TBL] [Abstract][Full Text] [Related]
9. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
10. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
11. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J; Baraliakos X; Listing J; Sieper J
Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
[TBL] [Abstract][Full Text] [Related]
12. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
Breedveld FC
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2273-7. PubMed ID: 16240851
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis.
Marzo-Ortega H; Emery P; McGonagle D
N Engl J Med; 2003 Jan; 348(4):359-61; author reply 359-61. PubMed ID: 12542065
[No Abstract] [Full Text] [Related]
14. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
[TBL] [Abstract][Full Text] [Related]
15. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor inhibitors in ankylosing spondylitis.
Reed MR; Taylor AL
Intern Med J; 2008 Oct; 38(10):781-9. PubMed ID: 18422565
[TBL] [Abstract][Full Text] [Related]
17. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
Berg PA
Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
[No Abstract] [Full Text] [Related]
18. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Mar; 46(3):439-41. PubMed ID: 17255137
[TBL] [Abstract][Full Text] [Related]
19. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
20. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
